• / Free eNewsletters & Magazine
  • / My Account
Home>Insiders>Thomas H. Lee

Thomas H. Lee

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Press Ganey Launches Segmentation White Paper

    Press Ganey Launches Segmentation White Paper

  2. Onxeo Announces First Outcomes of Livatag® Preclinical Plan

    Onxeo Announces First Outcomes of Livatag® Preclinical Plan

  3. Between Fed Lift-Off and Living in the New Neutral

    Ceridian CEN is set be acquired after shareholders finally approved the $36 per share offer from Thomas H . Lee Partners and Fidelity National Financial FNF. We expect the deal to be completed before the end of the year.

  4. Onxeo S.A.: Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

    Onxeo S.A.: Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

  5. UPDATE: A 3-year low for this contrarian indicator may be a screaming buy signal

    UPDATE: A 3-year low for this contrarian indicator may be a screaming buy signal

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.